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Purpose. To investigate the use of the weight-loss drugs rimonabant, sibutramine, and orlistat in primary care and to characterize
the patients receiving the drugs. Methods. In this retrospective, descriptive study, 300randomly selected patients having started
weight-lossdrug treatment at15primarycare centres were investigated usingthepatient’s medicalrecords andtheircomplete drug
purchase data. Results. Even though 48% ofthe patients speciﬁcally demanded drug treatment, 77% continued treatment less than
one year. 28% of rimonabant patients and 32% of sibutramine patients had a history of depression or antidepressant treatment.
41% of sibutramine patients had a history of hypertension and/or cardiovascular disease. 36% had no documented weight after
treatment initiation. Conclusions. These results suggest that weight-loss drug treatment was often initiated upon patient request
but was of limited clinical beneﬁt as it was managed in a large portion of Swedish primary carecenters.
1.Introduction
Obesity is a prevalent chronic condition which is associated
with signiﬁcant morbidity and mortality [1]. The prevalence
is increasing rapidly in all countries, with WHO estimating
1.6 billion overweight adults and 400 million obese adults
in 2005 [2]. Although not being one of the worst inﬂicted
countries, the prevalence of obesity in Sweden has also in-
creased substantially over the last decades, and it has been
estimated that 10% of both men and women are obese, and
a further 40% are overweight [3]. Consequently, there is an
urgent need for eﬀective life-style interventions and often
also pharmacological treatment.
The development of antiobesity medicines has been
problematic and characterized by heavy marketing followed
by withdrawals from the market after reports of safety prob-
lems, including pulmonary hypertension (aminorex), valvu-
lar lesions (dexfenﬂuramine-phentermine), and addiction
(amphetamine) [4]. This pattern has continued in recent
years with the withdrawal of rimonabant (Acomplia) in
October2008andsibutramine (Reductil,Reduxade,Zelium)
in January 2010 due to safety concerns[5, 6]. Currently, orli-
stat is the only registered weight-loss drug on the European
market, but new drugs are in the pipeline [7, 8].
In the metropolitan health region of Stockholm, Swe-
den, a model has been developed which includes horizon
scanning (to prepare for drugs to come), forecasting of drug
utilization and expenditures, critical drug evaluation, and
structured programs for the introduction and followup of
new drugs [9]. When rimonabant was given the marketing
approval in 2006, the subsequent marketing activities led to
concerns about improper use and inappropriate increase in
expenditure. Rimonabant was, therefore, one of the drugs
selectedforastructuredintroductionandfollowupprogram.
In 2006, the total expenditure for weight-loss drugs was 154
million SEK in Sweden [10].
This study is a characterization of the use of weight-
loss drugs in the primary health care setting of Stockholm
County. The aim was to analyse the utilization and eﬀective-
ness of the three weight-loss drugs rimonabant, sibutramine,2 Journal of Obesity
Table 1: The three weight-loss drugs on the Swedish market in
2008.
Rimonabant
Rimonabant (Acomplia) is a cannabinoid CB1-receptor earlierly
registered in Europe for the treatment of overweight with risk
factors (BMI over 27 with dyslipidemia or diabetes) or obesity
(BMI over 30) in combination with lifestyle interventions. In
Sweden, the drug was reimbursed only if BMI was over 28 with
dyslipidemia or diabetes, or if BMI was over 35 [11]. A
meta-analysis has shown a placebo-adjusted weight loss of 4.3kg
after one year of treatment [12]. Contraindications included
ongoing depression or treatment with antidepressant drugs [11].
Rimonabant was withdrawn from the market in October 2008
due to the risk of psychiatric side eﬀects [5].
Orlistat
Orlistat (Xenical) is a gastrointestinal lipase inhibitor registered
in Europe and the US for the treatment of overweight with risk
factors (BMI over 27 with dyslipidemia or diabetes) or obesity
(BMI over 30) in combination with diet interventions. In
Sweden, the drug is reimbursed only if BMI is over 28 with
dyslipidemia or diabetes, or if BMI is over 35 [13]. A
meta-analysis has shown a placebo-adjusted weight loss of 2.7kg
after one year of treatment [12]. Malabsorptionis a
contraindication [13].
Sibutramine
Sibutramine (Reductil) is a serotonin, norepinephrine, and
dopamine reuptake inhibitor earlierly registered in Europe for
the treatment of overweight with risk factors (BMI over 27 with
dyslipidemia or diabetes) or obesity (BMI over 30) in
combination with lifestyle interventions. In Sweden, the drug was
reimbursed only if BMI was over 28 with dyslipidemia or
diabetes, or if BMI was over 35 [14]. A meta-analysis has shown a
placebo-adjusted weight loss of 4.3kg after one year of treatment
[12]. Contraindications were amongothers cardiovascular
disease, psychiatric disease, ongoing treatment with
antidepressant or antipsychotic drugs, and uncontrolled
hypertension [14]. Sibutramine was withdrawn from the market
in January 2010 due to an increased risk of cardiovascular
incidents [6].
and orlistat (see Table 1) which were on the Swedish market
in2008.Rimonabantwaswithdrawn fromthemarkettoward
the end of the study period, which limits the possibility of
conducting a 1-year evaluation for this drug. Sibutramine
was withdrawn after the study period, while orlistat still
remains on the market.
2.Methods
2.1. Medical Record Data. We conducted a retrospective, de-
scriptive study based on data extracted from electronic med-
ical records in primary healthcare. All data were extracted
using Rave3 software (Medrave Software AB, Stockholm)
[15, 16]. The Rave3 software extracts data from the medical
recorddatabase in a systematic way making itpossible tolink
most of the recorded data such as diagnosis, laboratory
ﬁndings, and text registered in the medical record. A vali-
dation was done conﬁrming that the extracted data was in
agreement with the medical records. Rave3 performed well
regarding the extraction of data documented in association
with a speciﬁed term, but an additional manual analysis had
to be performed to include the missing medical data.
Atotalof36primary healthcarecentres(PHCs)compris-
ing the Southwest district of the Stockholm County Council
were invited to participate in the study. 24 of them used
electronic medical records adapted to the Rave3 software
and were thus able to participate. Among them, 15 practices
agreed to participate and were included in the study.
Speciﬁc parameters as well as unformatted medical
record information from November 1, 2005 to February 28,
2009 were centrally extracted with Rave3, anonymised, and
entered into a database for further analysis. Thus all patients
could be evaluated during at least 15 months after the
start of treatment. Data regarding diagnosis of depression,
antidepressant treatment, or earlier treatment with orlistat
or sibutramine were also extracted back to the year 2000
in order to obtain some important characteristics of the
patients before November 1, 2005.
2.2. Prescription Data. To assess to what extent the patients
redeemed their prescriptions, data from the medical records
were linked to data on dispensed drugs in the Swedish Pre-
scribed Drugregister [17].The NationalBoard ofHealthand
Welfareisresponsibleforkeepingthisregisterwhich contains
data on all prescription drugs dispensed in Sweden from
2005 and onwards, their amounts and dosages, expenditures
and reimbursement, as well as the age, the gender and the
unique identiﬁer (personal identiﬁcation number) of the
patient. Using anonymised record linkage, we analysed the
dispensing histories for all of patients’ prescriptions between
November 1, 2005 and February 28, 2009 to assess all the
drugs that the patients actually had purchased from the
pharmacy, regardless of the origins of the prescriptions. It
also permitted an analysis of the persistence of weight-loss
treatment.
The terminology and methodology used for measuring
persistence varies across studies [18]. We deﬁned persistence
as the total number of days on treatment measured by the
amount of drugs purchased from the pharmacy divided by
the usual number ofdosagesfor the drug. The reason for our
choice is that weight-loss drugs have not been indicated for
long-term risk reduction but for a limited period of weight-
loss treatment. The duration of treatment is, thus, more
important in this case than for chronic treatment where
adherence is more interesting. Deﬁned daily doses (DDD)
were not used due to the availability of sibutramine in
both 10-mg and 15-mg compositions, which would have
overestimated the treatment duration of this drug.
2.3. Statistics. Standard descriptive statistics (numbers, pro-
portions, median, interquartile range, and range) were used
todescribethestudycohortandtheutilizationpatterns.Data
are presented with 95% exact binomial conﬁdence intervals
(CI) for proportions, where appropriate.
2.4. Ethics. The study was approved by the regional ethics
committee.Journal of Obesity 3
3.Results
3.1. Population. The 15PHCs included were responsible for
a total of 205, 440 patients in 2008. Rave3 identiﬁed a total
of 876 patients who had commenced treatment with weight-
lossdrugsattheseprimary carecentresbetweenNovember1,
2006and November30, 2007, that is, a period of13 months.
370 patients (42%) had received rimonabant, 230 patients
(26%) had received orlistat, and 276 patients had received
sibutramine (32%). The number of unique patients was
829 due to the fact that an individual patient could have
started treatment with diﬀerent weight-loss drugs during
this time period. The present analysis was limited to 100
randomly chosen patients for each weight-loss drug, that is,
300patientsintotal.Thenumberofuniquepatientsanalysed
was 294.
3.2. Selection Bias. In order to detect possible selection bias,
wecharacterized theparticipating PHCsand comparedthem
to the nonincluded centres. The participating centres were
moreoftenpubliclymanaged andhadmorepatientsthanthe
nonparticipating centres. The proportion of older patients,
the number of visits per patient, the average drug expen-
diture per patient, and the proportion of prescriptions
for weight-loss drugs compared to the total amount of
prescriptions were similar. The population-base living next
to the centres was also similar, as evaluated by age spans,
unemployment, beneﬁciaries of social aid, immigrants, as
well as levels of education and proportions of low- and
high-income households. Thus, the comparison revealed no
potentially important diﬀerences between PHCs who partic-
ipated in the study and those who did not (data not shown).
3.3. Diabetes and/or Dyslipidemia. Of the patients who initi-
ated weight-loss drug treatment, 65% had a diagnosis of dia-
betes and/or dyslipidemia, treatment for such a diagnosis, or
laboratorytestsindicatingsuchacondition(seeTable2).The
incidencewasevenlydistributedamongthethreeweight-loss
drugs. 32% had treatment for diabetes and/or dyslipidemia.
3.4. Cardiovascular Disease. Cardiovascular disease or un-
controlled hypertension was contraindications for treatment
with sibutramine. 41% of the patients who started treatment
with sibutramine had at least one diagnosis or treatment
consistent with hypertension and/or other cardiovascular
disease (see Table 2). The ﬁrst or last blood pressure during
the study period was above 140/90mmHg in another 7% of
the patients.
3.5. Psychiatric Disease. Contraindications for rimonabant
and sibutramine included ongoing depression or treatment
with antidepressants. 28% of the patients who started treat-
ment with rimonabant and 32% of the patients with sibu-
tramine had a diagnosis of depression and/or antidepressant
treatment during the study period (see Table 2). Whether
the depression and/or antidepressant treatment was present
before the initiation of weight-loss drug treatment, occurred
during the treatment, or occurred after the treatment, has
not been analysed. 58% of rimonabant patients and 56%
of sibutramine patients had signs of psychiatric problems in
their medical history (anxiety, sleeping disorder, stress disor-
ders, professional burnout, eating disorder, or treatment for
such conditions). Psychiatric disease was a contraindication
for sibutramine. Patients treated with orlistat had a slightly
higher frequency of both depression or treatment of depres-
sion andotherpsychiatric problems,butsuch patientscanbe
treated with the drug without additional risk.
3.6. Initiative to Treat. In 48% of the cases, it was clearly
stated in the medical ﬁle that the patient asked for treatment
with weight-loss drugs, often with the wish for a speciﬁc
drug. It was unclear whether the patient or the prescribing
physician had taken the initiative to drug treatment in 50%
of the cases. In only 2% of the cases, it was clearly stated that
the physician had proposed treatment with the weight-loss
drug.
3.7. Prescription of Other Weight-loss Drugs. In total, 40%
of the patients had tried one or both of the other weight-
loss drugs during the study period −48% of those receiving
rimonabant, 46%ofthosereceiving sibutramine, and27%of
those receiving orlistat.
3.8. Weight Change. In 51% of all 300 patients, Rave3 found
no documentation of the patient’s weight under the right
heading in the electronic medical record. We therefore also
conducted a manual evaluation of the case records. We
limited this analysis to patients having been prescribed the
weight-loss drug for at least one year since a meaningful
eﬀect on weight requires a long period of treatment. Among
the 300 manually analysed patient records, 100 patients had
been prescribed the drug for one year or longer −48 had had
rimonabant, 31 sibutramine, and 21 orlistat. These patients
were further analysed regarding the last documented weight
after at least 9 months of treatment. In 62 patients the data
were insuﬃcient to evaluate changes in weight. 28 patients
had lost weight, and 10 patients had an unchanged weight.
Only 18 out of the 300 patients, that is, 6% had the drug
prescribed for at least one year and a conﬁrmed clinically
relevant weight-loss of at least 5% after at least 9 months of
treatment (see Figure 1). Whether the weight loss achieved
depended on the drug treatment or other factors cannot be
concluded in this study, and possible long-term changes in
weight among other patients could not be deduced from the
medical records.
3.9. Documentation of Weight. 26% of the patients who had
been prescribed the weight-loss drug for at least one year
lacked documentation of his/her initial weight or weight
within 3 months prior to the prescription. 36% lacked
a followup weight on any occasion after the initiation of
treatment. For these reasons, it was impossible to draw
any conclusions regarding treatment eﬃcacy in 45% of the
patients. This indicates that the management and followup
of patients treated with weight-loss drugs was inadequate.4 Journal of Obesity
Table 2: Patient characteristics (Values within parentheses are 95% Conﬁdence Intervals (CI). CIs around medians calculated by binomial
method, and around relative frequencies by exact binomial method.).
All patients
(N = 300)
Rimonabant patients
(N = 100)
Sibutramine patients
(N = 100)
Orlistat patients
(N = 100)
Median age 47 55 (50–57) 42 (40–45) 49 (45–53)
P25 39 44 35 39
P75 59 63 54 59
Age span 17–96 23–78 17–76 21–96
Men 23% 23% (15–32) 18% (11–27) 28% (19–38)
Women 77% 77% (68–85) 82% (73–89) 72% (62–81)
Body Mass Index
No BMI 29% 25% (17–35) 31% (22–41) 31% (22–41)
BMI <28kg/m2 5% 5% (2–11) 3% (0.6–9) 7% (3–14)
BMI 28–35kg/m2 32% 36% (27–46) 27% (19–37) 32% (23–47)
BMI >35kg/m2 34% 34% (25–44) 39% (29–49) 30% (21–40)
Concomitant diseases and treatments
Diabetes 24% 31% (22–41) 13% (7–21) 28% (19–38)
Dyslipidemia 63% 72% (62–81) 60% (50–70) 57% (47–67)
Diabetes, and/or dyslipidemia 65% 75% (65–83) 60% (50–70) 61% (51–71)
Treatment for diabetes 19% 26% (18–36) 9% (4–16) 22% (14–31)
Treatment for dyslipidemia 24% 36% (27–46) 15% (9–24) 21% (13–30)
Treatment for diabetes and/or
dyslipidemia 32% 43% (33–53) 21% (13–30) 33% (24–43)
Cardiovascular disease and/or
hypertension 51% 66% (56–75) 41% (31–51) 47% (37–57)
Depression and/or antidepressant
treatment 34% 28% (19–38) 32% (23–42) 42% (32–52)
Psychiatric problems 60% 58% (48–68) 56% (46–66) 66% (56–75)
Pain and other musculoskeletal problems 66% 67% (57–76) 65% (55–74) 66% (56–75)
100
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Figure 1: The weight loss process.
3.10. Treatment Persistence. Although 33% of the 300 pa-
tients in the present study had been prescribed drug
treatment for at least one year, it appears that 23% of them
actuallypurchasedthedrugsforatleastoneyearoftreatment
−32% on rimonabant, 25% on sibutramine, and 13% on
orlistat (see Figure 2). Among the 300 patients, 6% never
ﬁlled the ﬁrst prescription at the pharmacy.
3.11.TreatmentDiscontinuation. Mostcommonly,noreason
for discontinuation was documented (65% of the patients).
The most common cause for discontinuation of rimonabant
was prescriptionuntil, orpast, thedateof marketwithdrawal
which is reported under “Other” (see Table 3). Other
common reasons included side eﬀects reported by 15%
and dissatisfaction with the eﬀect reported by 11%. TheJournal of Obesity 5
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Figure 2: Percentage of patients left on treatment.
most commonly documented causes for discontinuation for
patients having received sibutramine were dissatisfaction
with the eﬀectiveness of the drug and side eﬀects reported by
11%each. 7%ofthepatientshaving receivedorlistat stopped
treatment due to dissatisfaction with the eﬀectiveness, and
4% quitted due to side eﬀects.
4.Discussion
In this retrospective, descriptive study, prescription routines
for300randomlyselectedpatientshaving started weight-loss
drug treatment at 15 primary care centres were investigated
using patients’ electronic medical records and their complete
drugpurchase data from the Swedish National Board ofWel-
fare. Generally, patients who received weight-loss drugs had
a poor health status with cardiovascular disease, diabetes,
dyslipidemia, depression, and other psychiatric problems.
Many hadattemptedtreatment with otherweight-loss drugs,
and a signiﬁcant proportion hadl i s t e dc o n t r a - i n d i c a t i o n s
to the prescribed drug. Even though the patients often spe-
ciﬁcally demandedweight-loss drugtreatment from the doc-
tor, 77% continued treatment for less than one year. A large
proportion of the patients were not weighed prior to
treatment initiation and not followed within the context of
a structured lifestyle intervention.
Prescription of weight-loss drugs was the most common
in the Stockholm County Council than elsewhere in the
country [10]. Our results are thus not generally applicable
throughout Sweden but suggest problems that probably
exist to varying degrees at many primary care centres.
However, our earlier analysis of national prescription data
for weight-loss drugs in Sweden showed similar results with
a frequent history of use of other weight-loss drugs and
antidepressant drugs, and with many patients who were not
on drug treatment for diabetes and/or dyslipidemia [10].
Needless to say, the management of overweight patients
might vary between diﬀerent units and prescribers.
The present results suggest that many patients were
prescribed weight-loss drugs despite possible or deﬁnite
contraindications. It is remarkable that information about
the key variable of interest, that is, body weight, was so often
lacking in the medical records. All three weight loss drugs
were only licensed for weight-loss treatment in combination
with a structured weight loss program including exercise
and diet. Regular followup including weight measurements
both before and during such a program is essential and
should be a mainstay in the treatment of overweight. The
moderate weight loss seen in clinical trials of these drugs
[12] is not generally applicable to short-term treatments
without followup. Frequent prescriptions for patients with
contraindications or otherconditions prompting forcaution
are an important safety aspect. Both rimonabant and sibu-
tramine have been withdrawn from the market. The present
data support the wisdom of these withdrawals.
Even though advertising for prescription drugs is illegal
in the European Union, it was often stated in the medical
records that the reason for consulting the doctor was to
obtain weight-loss drug treatment, often with the wish for
a speciﬁc drug. Safety and eﬃcacy concerns normally appear
to have a major inﬂuence on the use ofnew drugs in primary
care [19]. However, denying treatment to a patient who
through media, friends, the Internet, or other sources has
got the impression that there are eﬀective drugs for losing
weight isadelicatetask andrequiresknowledgeonthebehalf
of the prescriber in order to motivate his/her decision to
treat or not to treat with a drug. Additional possibilities to
advertise directly to patients would probablyfurther increase
the problems described in this article [20, 21].
In our earlier analysis of the national prescription data,
we found that only 1/3 of the patients who started treatment
with rimonabant during its ﬁrst six weeks on the market
continued the treatment after 6 months [10]. A Canadian
evaluationofthetreatment persistence with sibutramine and
orlistat showed that less than 10% of the patients remained
on treatment after one year, and less than 2% continued
treatment after 2 years [22]. Maintaining the patients on
treatment has been a problem also in the clinical trials [12,
23]. For example, the drop-out rate in the clinical trials of
rimonabant was 35–50% during the ﬁrst year [24–27]. Lack
of persistence with treatment was a major problem in this
study as well. Lack of eﬃcacy or adverse events are the likely
major causes of premature discontinuation of treatment.
However, the reasons are seldomclearly stated in the medical
record.
4.1. The Future. It is likely that the trend of informed
patients actively seeking medical treatment for lifestyle-
related conditions will increase. It might be problematic to
achieve a rational use of drugs which are seldom prescribed6 Journal of Obesity
Table 3: Reasons for discontinuation.
Unclear Not
terminated Other Lack of
eﬀect
Neurological
side eﬀects
Psychiatric
side eﬀects
Gastrointestinal
side eﬀects
Cardiovascular
side eﬀects
Other side
eﬀects
Rimonabant
(N = 100) 53% 0% 21% 11% 3% 5% 4% 0% 3%
Sibutramine
(N = 100) 65% 9% 4% 11% 1% 4% 1% 4% 1%
Orlistat
(N = 100) 78% 6% 5% 7% 0% 0% 2% 0% 2%
bytheaveragegeneralpractitioner, especiallyifthetreatment
isnewonthemarket.Unbiasedcontinuedmedicaleducation
about new drugs appears to be important, and electronic
tools for prospective data collection could possibly improve
the quality regarding both initiation of therapy and followup
of particularly sensitive and/or expensive drug treatments.
These results show the importance of prioritizing the devel-
opment of such assistance.
5.Conclusions
In conclusion, this observational study suggests that the
treatment with weight-loss drugs was oflimited clinical ben-
eﬁt the way they were used in a large proportion of Swedish
primary care. Also, our results indicate that eﬀective models
are needed to evaluate the risks and beneﬁts of treatment
with life-style drugs in the everyday clinical setting.
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